1-3 of 3
Hubert Chuang, MD
Close
Sort by
Journal Articles

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Michelle A. Fanale, MD, Fredrick B. Hagemeister, MD, Luis Fayad, MD, Yasuhiro Oki, MD, Nathan Fowler, MD, Jorge Romaguera, MD, Nina Shah, Hubert Chuang, MD, Lei Feng, MS, Sandra B Horowitz, PharmD, Emily Wesson, APN, Toni Y Hutto, BS, Tariq Muzzafar, MD, Felipe Samaniego, MD, R Eric Davis, MD
Journal: Blood
Blood (2014) 124 (21): 1744.
https://doi.org/10.1182/blood.V124.21.1744.1744
Published: 2014
Journal Articles

The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma

Yasuhiro Oki, MD, Hubert Chuang, MD, Beth Chasen, MD, Tinsu Pan, PhD, Michelle A. Fanale, MD, Bouthaina S. Dabaja, MD, Nathan H Fowler, MD, Jorge Enrique E Romaguera, MD, Luis E Fayad, MD, Fredrick B Hagemeister, MD, Alma Rodriguez, Sattva S. Neelapu, MD, Felipe Samaniego, MD, MPH, Larry W Kwak, MD, PhD, Anas Younes, MD
Journal: Blood
Blood (2012) 120 (21): 1529.
https://doi.org/10.1182/blood.V120.21.1529.1529
Published: 2012
Journal Articles

Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma

Bouthaina S. Dabaja, MD, Jack Phan, MD PhD, L. Jeffrey Medeiros, MD, F.B. Hagemeister, MD, Hubert Chuang, MD, Luis Fayad, MD, Ferial Shihadeh, MD, Pamela Allen, PhD, Christine Wogan, MS, Maria A. Rodriguez, MD
Journal: Blood
Blood (2011) 118 (21): 2695.
https://doi.org/10.1182/blood.V118.21.2695.2695
Published: 2011